Pancreatic Cancer Research

ResearcherNara Medical UniversityNo recent work listed

Yoshiyuki Nakajima

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112625957. Sources: OpenAlex.

Their work

Papers
23 (first author 0, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
47
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 2 papers · 2014: none · 2015: 9 papers · 2016: 7 papers

Papers 23

  1. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreati… Co-author DOI 10.1002/jhbp.318↗
  2. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. Last author DOI 10.1002/jhbp.320↗
  3. Adjuvant Hepatic Arterial Infusion Chemotherapy After Resection for Pancreatic Cancer Using Coaxial Catheter-Port System Compared with Conventional System. Co-author DOI 10.1007/s00270-016-1292-7↗
  4. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic … Co-author DOI 10.1007/s00280-015-2928-z↗
  5. Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer. Co-author DOI 10.1007/s00330-015-3999-2↗
  6. Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. Last author DOI 10.1016/j.amjsurg.2015.10.034↗
  7. Grade B pancreatic fistulas do not affect survival after pancreatectomy for pancreatic cancer: A multicenter observational study. Co-author DOI 10.1016/j.surg.2016.02.032↗
  8. Importance of resectability status in neoadjuvant treatment for pancreatic cancer. Last author DOI 10.1002/jhbp.258↗
  9. Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. Last author DOI 10.1007/s00268-015-3205-3↗
  10. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. Last author DOI 10.1007/s00423-015-1304-0↗
  11. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. Last author DOI 10.1007/s00535-014-1005-4↗
  12. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. Co-author DOI 10.1007/s11605-014-2637-7↗
  13. Potential role of surgical resection for pancreatic cancer in the very elderly. Last author DOI 10.1016/j.pan.2015.03.015↗
  14. Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy. Last author DOI 10.1097/mpa.0000000000000395↗
  15. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. Last author DOI 10.1186/s13046-015-0144-7↗
  16. Clinical significance of CD155 expression in human pancreatic cancer. Last author PMID 25862891↗
  17. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. Last author DOI 10.1007/s00534-012-0532-8↗
  18. Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments:… Co-author DOI 10.1007/s00534-013-0616-0↗
  19. PCA-1/ALKBH3 contributes to pancreatic cancer by supporting apoptotic resistance and angiogenesis. Last author DOI 10.1158/0008-5472.can-12-0328↗
  20. Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabin… Co-author DOI 10.2214/ajr.11.8008↗
  21. [Resection of the remnant pancreas for recurrent pancreatic cancer after distal pancreatectomy-a case report]. Last author PMID 23267918↗
  22. Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. Last author DOI 10.1007/s00534-010-0336-7↗
  23. Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer. Co-author PMID 22110218↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Sho · 23 shared papers, 2011–2016 · strength 0.97
  2. Takahiro Akahori · 16 shared papers, 2011–2016 · strength 0.72
  3. Shoichi Kinoshita · 14 shared papers, 2012–2016 · strength 0.63
  4. Minako Nagai · 13 shared papers, 2015–2016 · strength 0.61
  5. Satoshi Nishiwada · 11 shared papers, 2015–2016 · strength 0.52
  6. Kimihiko Kichikawa · 10 shared papers, 2011–2016 · strength 0.44
  7. Hideyuki Nishiofuku · 9 shared papers, 2011–2016 · strength 0.38
  8. Sohei Satoi · 8 shared papers, 2013–2016 · strength 0.34
  9. Toshihiro Tanaka · 8 shared papers, 2011–2016 · strength 0.31
  10. Hiroaki Yanagimoto · 6 shared papers, 2015–2016 · strength 0.27
  11. Satoshi Yasuda · 6 shared papers, 2012–2015 · strength 0.23
  12. Ichiro Yamato · 6 shared papers, 2011–2015 · strength 0.21
  13. Hiroki Yamaue · 5 shared papers, 2013–2016 · strength 0.20
  14. Chiho Ohbayashi · 4 shared papers, 2015–2016 · strength 0.20
  15. Tomohisa Yamamoto · 4 shared papers, 2015–2016 · strength 0.18
  16. Yoshiaki Murakami · 4 shared papers, 2015–2016 · strength 0.17
  17. Masanao Kurata · 4 shared papers, 2015–2016 · strength 0.17
  18. Kenichiro Uemura · 4 shared papers, 2015–2016 · strength 0.17
  19. Takumi Fukumoto · 4 shared papers, 2015–2016 · strength 0.17
  20. Ippei Matsumoto · 4 shared papers, 2015–2016 · strength 0.17
  21. Michiaki Unno · 4 shared papers, 2015–2016 · strength 0.17
  22. Fuyuhiko Motoi · 4 shared papers, 2015–2016 · strength 0.17
  23. Manabu Kawai · 4 shared papers, 2015–2016 · strength 0.17
  24. Goro Honda · 4 shared papers, 2015–2016 · strength 0.17
  25. A‐Hon Kwon · 4 shared papers, 2013–2016 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.